Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Has Nasal Naloxone Nod For First US Narcan Rival

Executive Summary

Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.

You may also be interested in...

Teva Sees Off Emergent’s US Narcan Appeal In ‘A Close Case’

Shortly after agreeing to provide the state of Texas with its generic version of Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray, Teva has secured victory in patent-invalidity proceedings.

Teva And Sandoz Go Head-To-Head On US Narcan

Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.

Emergent Makes Plans For Narcan Nasal Spray Competition

Adapt Pharma parent company Emergent BioSolutions has revealed plans to defend its Narcan nasal naloxone brand against potential generic competition in the US, including through an authorized generic deal with a major generics firm, as it awaits the outcome of litigation with Teva.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts